Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results View HTML
Toggle Summary Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock View HTML
Toggle Summary Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy View HTML
Toggle Summary Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura View HTML
Toggle Summary Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants View HTML
Toggle Summary Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results View HTML
Toggle Summary Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed View HTML
Toggle Summary Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura™ Following Positive DMC Review View HTML
Toggle Summary Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy View HTML